术前左心室功能不全患者心脏术后血管麻痹性休克应用血管加压素的倾向评分分析
这项回顾性队列研究纳入2007年至2017年间1156例心脏术后血管麻痹性休克(平均动脉压<65 mmHg且对液体复苏无反应、心脏指数>2.20 L/min·m²)合并术前左心室功能不全(左心室射血分数≤35%、左心室舒张末期内径≥60 mm、纽约心脏协会分级≥III级)的患者。通过倾向评分匹配得到338例(血管加压素组169例,去甲肾上腺素组169例)风险特征相似的患者。匹配后两组主要结局(30天死亡率、机械通气>48小时、心脏再手术、体外膜氧合、卒中、急性肾损伤)无显著差异(50.89% vs 58.58%,P=0.155)。但血管加压素组次要结局中房颤(11.83% vs 20.12%,P=0.038)和室性心律失常(14.20% vs 24.85%,P=0.014)发生率显著高于去甲肾上腺素组。作者认为血管加压素不能改善此类患者的术后结局,作为一线升压药应谨慎使用。
要点
- 在术前左心室功能不全的心脏术后血管麻痹性休克患者中,倾向评分匹配后血管加压素组与去甲肾上腺素组主要结局无显著差异(50.89% vs 58.58%,P=0.155)。
- 血管加压素组房颤发生率显著高于去甲肾上腺素组(11.83% vs 20.12%,P=0.038)。
- 血管加压素组室性心律失常发生率显著高于去甲肾上腺素组(14.20% vs 24.85%,P=0.014)。
- 作者认为,与去甲肾上腺素相比,血管加压素不能改善术前左心室功能不全患者心脏术后的结局。
- 作者建议,在心脏术后血管麻痹性休克中,血管加压素作为一线升压药应谨慎使用。
适用人群与场景
- 2007年至2017年心脏术后出现血管麻痹性休克且合并术前左心室功能不全的患者。
- 术前左心室功能不全定义:左心室射血分数≤35%,或左心室舒张末期内径≥60 mm,或纽约心脏协会分级≥III级。
- 血管麻痹性休克定义:平均动脉压<65 mmHg且对液体复苏无反应,心脏指数>2.20 L/min·m²。
诊断标准与关键阈值
- 血管麻痹性休克:平均动脉压<65 mmHg,对液体复苏无反应,心脏指数>2.20 L/min·m²。
- 术前左心室功能不全:左心室射血分数≤35%,或左心室舒张末期内径≥60 mm,或纽约心脏协会分级≥III级。
处置流程与药物剂量
- 血管加压素组:血管加压素0.02-0.07 U/min。
- 去甲肾上腺素组:去甲肾上腺素10-60 μg/min。
研究设计与关键结果
- 研究类型:回顾性队列研究;样本量:1156例患者,倾向评分匹配后338例(血管加压素组169例,去甲肾上腺素组169例)。
- 主要结局(30天死亡率、机械通气>48小时、心脏再手术、体外膜氧合、卒中、急性肾损伤)在血管加压素组与去甲肾上腺素组间无显著差异(50.89% vs 58.58%,P=0.155)。
- 次要结局中,血管加压素组房颤发生率高于去甲肾上腺素组(11.83% vs 20.12%,P=0.038)。
- 次要结局中,血管加压素组室性心律失常发生率高于去甲肾上腺素组(14.20% vs 24.85%,P=0.014)。
证据类型、等级与局限
- 证据类型:回顾性队列研究,采用倾向评分匹配分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与去甲肾上腺素相比,血管加压素不能改善术前左心室功能不全患者心脏术后的结局。
- 作者建议,在心脏术后血管麻痹性休克中,血管加压素作为一线升压药应谨慎使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Postoperative vasoplegic shock after cardiac surgery seems to be a frequent complication with poor outcomes. We hypothesized that vasopressin may increase the risk of poor outcomes in patients with preoperative Left Ventricular Dysfunction (pLVD) rather than norepinephrine. The aim of this study was to assess whether vasopressin is superior to norepinephrine to improve outcomes in patients with pLVD after cardiac surgery.
METHODS: This retrospective cohort study included 1,156 patients with postoperative vasoplegic shock (mean arterial pressure <65 mmHg resistant to fluid challenge and cardiac index >2.20 L/min m) and pLVD (left ventricular ejection fraction ≤35%, left ventricular end-diastolic diameter ≥60 mm, New York Heart Association ≥III) from 2007 to 2017. To address any indicated biases, we derived a propensity score predicting the functions of vasopressin (0.02-0.07 U/min) and norepinephrine (10-60 μg/min) on postoperative vasoplegic shock. The primary outcomes were 30-day mortality, mechanical ventilation more than 48 h, cardiac reoperation, extracorporeal membrane oxygenation, stroke, and acute kidney injury, whereas the secondary outcomes included infection, septic shock, atrial fibrillation and ventricular arrhythmias.
RESULTS: There were 338 patients (169 vasopressin and169 norepinephrine) with a similar risk profile in propensity score-matched cohort. In propensity-matched patients, the primary outcomes of vasopressin and norepinephrine showed no significant difference (50.89% vs. 58.58%, P = 0.155). However, compared with norepinephrine, secondary outcomes of vasopressin were increased due to the high rate of atrial fibrillation (11.83% vs. 20.12%, P = 0.038) and ventricular arrhythmias (14.20% vs. 24.85%, P = 0.014).
CONCLUSIONS: Compared with norepinephrine, vasopressin could not improve the postoperative outcomes in patients with pLVD after cardiac surgery. Vasopressin should be cautious to be used as a first-line vasopressor agent in postcardiac vasoplegic shock.
参考来源
- Cheng Y, Pan T, Ge M, et al. Evaluation of Vasopressin for Vasoplegic Shock in Patients With Preoperative Left Ventricular Dysfunction After Cardiac Surgery: A Propensity-Score Analysis. Shock. 2018. PMID: 29424795. doi:10.1097/SHK.0000000000001114
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。